Gong Yuzhi (Chinese: 龚育之; 26 December 1929 – 12 June 2007) was a Chinese Communist Party theorist and politician. He was a representative of the 15th National Congress of the Chinese Communist Party. He was a member of the 5th, 6th, 7th, and 8th...
Gong Ke (Chinese: 龚克; born June 1955) is a Chinese electronic engineer and administrator who served as president of Tianjin University from 2006 to 2011 and president of Nankai University from 2011 to 2018. He was an alternate of the 18th Central...
Gong Yinbing (Chinese: 龚饮冰; 1896 – 26 June 1976) was a Chinese banker and politician. He was a delegate to the 6th National Congress of the Chinese Communist Party. He was a delegate to the 1st National People's Congress and the 2nd and 3rd Standing...
Pang Xianzhi (Chinese: 逄先知; pinyin: Páng Xiānzhī; born October 1929) is a Chinese historian and politician who served as director of the Party Documents Research Office of the Central Committee of the Chinese Communist Party from 1991 to 2002. Pang...
Emperor Gong of Jin (simplified Chinese: 晋恭帝; traditional Chinese: 晉恭帝; pinyin: Jìn Gōng Dì; Wade–Giles: Chin Kung-ti; 386 – October or November 421), personal name Sima Dewen (Chinese: 司馬德文; pinyin: Sīmǎ Déwén), was the last emperor of the Eastern...
Yu Guangyuan (Chinese: 于光遠; pinyin: Yú Guāngyuǎn; born as 郁鐘正; pinyin: Yù Zhōngzhèng; 5 July 1915 – 23 September 2013) was a Chinese economist, philosopher, and a senior official of the People's Republic of China. Yu was recognized as one of the...
The Literature Research Office (Chinese: 中共中央文献研究室), or the Documentation Research Office of the Central Committee of the Chinese Communist Party, was an office of the now-defunct Literature Editorial Committee of the CCP Central Committee,...
Wan Gang (Chinese: 万钢; pinyin: Wàn Gāng, born August 1952) is a Chinese expert on automobiles and retired politician, who served as the minister of science and technology from 2007 to 2018. The chairman of the China Zhi Gong Party from 2007 to 2022,...
Cadonilimab is a PD-1/CTLA-4 bispecific monoclonal antibody developed to treat a variety of solid cancer types. In June, 2022 it was approved in China "for use in patients with relapsed or metastatic cervical cancer (r/mCC) who have progressed on or...